vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Molson Coors Beverage Company (TAP). Click either name above to swap in a different company.
Molson Coors Beverage Company is the larger business by last-quarter revenue ($3.1B vs $2.8B, roughly 1.1× Bausch Health Companies Inc.). Molson Coors Beverage Company runs the higher net margin — 6.7% vs -3.7%, a 10.4% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 6.1%). Molson Coors Beverage Company produced more free cash flow last quarter ($1.1B vs $403.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -9.8%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Molson Coors Beverage Company is a Canadian-American multinational drink and brewing company headquartered in Chicago, Illinois and Montreal, Quebec.
BHC vs TAP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $3.1B |
| Net Profit | $-103.0M | $209.3M |
| Gross Margin | — | 31.0% |
| Operating Margin | 17.0% | — |
| Net Margin | -3.7% | 6.7% |
| Revenue YoY | 9.3% | 6.1% |
| Net Profit YoY | -205.1% | -28.7% |
| EPS (diluted) | $-0.30 | $1.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $3.1B | ||
| Q4 25 | $2.8B | $3.1B | ||
| Q3 25 | $2.7B | $3.5B | ||
| Q2 25 | $2.5B | $3.7B | ||
| Q1 25 | $2.3B | $2.7B | ||
| Q4 24 | $2.6B | $3.2B | ||
| Q3 24 | $2.5B | $3.6B | ||
| Q2 24 | $2.4B | $3.8B |
| Q1 26 | — | $209.3M | ||
| Q4 25 | $-103.0M | $238.3M | ||
| Q3 25 | $179.0M | $-2.9B | ||
| Q2 25 | $148.0M | $428.7M | ||
| Q1 25 | $-58.0M | $121.0M | ||
| Q4 24 | $98.0M | $287.8M | ||
| Q3 24 | $-85.0M | $199.8M | ||
| Q2 24 | $10.0M | $427.0M |
| Q1 26 | — | 31.0% | ||
| Q4 25 | — | 31.0% | ||
| Q3 25 | — | 33.7% | ||
| Q2 25 | — | 34.3% | ||
| Q1 25 | — | 31.6% | ||
| Q4 24 | — | 32.0% | ||
| Q3 24 | — | 33.4% | ||
| Q2 24 | — | 34.6% |
| Q1 26 | — | — | ||
| Q4 25 | 17.0% | 10.4% | ||
| Q3 25 | 23.1% | -98.5% | ||
| Q2 25 | 17.5% | 15.6% | ||
| Q1 25 | 12.2% | 6.9% | ||
| Q4 24 | 21.8% | 12.0% | ||
| Q3 24 | 12.7% | 12.5% | ||
| Q2 24 | 16.2% | 15.6% |
| Q1 26 | — | 6.7% | ||
| Q4 25 | -3.7% | 7.6% | ||
| Q3 25 | 6.7% | -84.0% | ||
| Q2 25 | 5.8% | 11.5% | ||
| Q1 25 | -2.6% | 4.5% | ||
| Q4 24 | 3.8% | 8.9% | ||
| Q3 24 | -3.4% | 5.5% | ||
| Q2 24 | 0.4% | 11.1% |
| Q1 26 | — | $1.22 | ||
| Q4 25 | $-0.30 | $1.32 | ||
| Q3 25 | $0.48 | $-14.79 | ||
| Q2 25 | $0.40 | $2.13 | ||
| Q1 25 | $-0.16 | $0.59 | ||
| Q4 24 | $0.24 | $1.39 | ||
| Q3 24 | $-0.23 | $0.96 | ||
| Q2 24 | $0.03 | $2.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $896.5M |
| Total DebtLower is stronger | $20.8B | $3.9B |
| Stockholders' EquityBook value | $-554.0M | $10.4B |
| Total Assets | $26.4B | $22.7B |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $896.5M | ||
| Q4 25 | $1.3B | $896.5M | ||
| Q3 25 | $1.3B | $950.2M | ||
| Q2 25 | $1.7B | $613.8M | ||
| Q1 25 | $1.1B | $412.7M | ||
| Q4 24 | $1.2B | $969.3M | ||
| Q3 24 | $719.0M | $1.0B | ||
| Q2 24 | $595.0M | $1.6B |
| Q1 26 | — | $3.9B | ||
| Q4 25 | $20.8B | $6.3B | ||
| Q3 25 | $21.0B | $6.3B | ||
| Q2 25 | $21.7B | $6.3B | ||
| Q1 25 | $21.5B | $6.2B | ||
| Q4 24 | $21.6B | $6.1B | ||
| Q3 24 | $21.5B | $6.2B | ||
| Q2 24 | $21.7B | $7.0B |
| Q1 26 | — | $10.4B | ||
| Q4 25 | $-554.0M | $10.2B | ||
| Q3 25 | $-565.0M | $10.3B | ||
| Q2 25 | $-764.0M | $13.4B | ||
| Q1 25 | $-1.2B | $13.1B | ||
| Q4 24 | $-1.3B | $13.1B | ||
| Q3 24 | $-1.2B | $13.3B | ||
| Q2 24 | $-1.2B | $13.2B |
| Q1 26 | — | $22.7B | ||
| Q4 25 | $26.4B | $22.7B | ||
| Q3 25 | $26.8B | $22.9B | ||
| Q2 25 | $27.3B | $26.8B | ||
| Q1 25 | $26.4B | $25.9B | ||
| Q4 24 | $26.5B | $26.1B | ||
| Q3 24 | $26.5B | $26.6B | ||
| Q2 24 | $26.5B | $27.4B |
| Q1 26 | — | 0.37× | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.61× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | — |
| Free Cash FlowOCF − Capex | $403.0M | $1.1B |
| FCF MarginFCF / Revenue | 14.4% | 36.5% |
| Capex IntensityCapex / Revenue | 3.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $2.5B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $495.0M | $540.7M | ||
| Q3 25 | $405.0M | $616.1M | ||
| Q2 25 | $289.0M | $718.3M | ||
| Q1 25 | $211.0M | $-90.7M | ||
| Q4 24 | $601.0M | $494.5M | ||
| Q3 24 | $405.0M | $521.2M | ||
| Q2 24 | $380.0M | $869.2M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $403.0M | $357.8M | ||
| Q3 25 | $314.0M | $483.0M | ||
| Q2 25 | $190.0M | $555.0M | ||
| Q1 25 | $96.0M | $-328.0M | ||
| Q4 24 | $495.0M | $383.4M | ||
| Q3 24 | $334.0M | $350.4M | ||
| Q2 24 | $302.0M | $691.7M |
| Q1 26 | — | 36.5% | ||
| Q4 25 | 14.4% | 11.4% | ||
| Q3 25 | 11.7% | 13.9% | ||
| Q2 25 | 7.5% | 14.8% | ||
| Q1 25 | 4.2% | -12.2% | ||
| Q4 24 | 19.3% | 11.8% | ||
| Q3 24 | 13.3% | 9.7% | ||
| Q2 24 | 12.6% | 18.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 5.9% | ||
| Q3 25 | 3.4% | 3.8% | ||
| Q2 25 | 3.9% | 4.4% | ||
| Q1 25 | 5.1% | 8.8% | ||
| Q4 24 | 4.1% | 3.4% | ||
| Q3 24 | 2.8% | 4.7% | ||
| Q2 24 | 3.2% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.27× | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 1.95× | 1.68× | ||
| Q1 25 | — | -0.75× | ||
| Q4 24 | 6.13× | 1.72× | ||
| Q3 24 | — | 2.61× | ||
| Q2 24 | 38.00× | 2.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
TAP
Segment breakdown not available.
